Analysts Set Expectations for MiMedx Group Q1 Earnings

MiMedx Group, Inc (NASDAQ:MDXG) – Equities researchers at Northland Securities issued their Q1 2026 earnings per share (EPS) estimates for MiMedx Group in a note issued to investors on Thursday, February 26th. Northland Securities analyst C. Byrnes forecasts that the company will post earnings of ($0.03) per share for the quarter. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Northland Securities also issued estimates for MiMedx Group’s Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.04 EPS and FY2026 earnings at $0.04 EPS.

Several other research firms have also issued reports on MDXG. UBS Group set a $10.00 target price on MiMedx Group in a research note on Monday, February 23rd. Lake Street Capital decreased their target price on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 20th. Citigroup began coverage on MiMedx Group in a research note on Monday, February 23rd. They set a “market outperform” rating for the company. Weiss Ratings restated a “hold (c)” rating on shares of MiMedx Group in a research report on Monday, December 29th. Finally, Mizuho reduced their target price on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Wednesday, December 17th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.60.

MiMedx Group Trading Down 0.2%

Shares of MiMedx Group stock opened at $4.88 on Monday. The firm has a market cap of $725.01 million, a price-to-earnings ratio of 15.25 and a beta of 1.59. MiMedx Group has a twelve month low of $4.71 and a twelve month high of $8.43. The business has a 50-day moving average price of $5.65 and a 200-day moving average price of $6.55. The company has a quick ratio of 3.92, a current ratio of 4.32 and a debt-to-equity ratio of 0.06.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. MiMedx Group had a return on equity of 29.37% and a net margin of 11.60%.The firm had revenue of $118.10 million for the quarter, compared to analysts’ expectations of $106.78 million.

Hedge Funds Weigh In On MiMedx Group

Several institutional investors have recently added to or reduced their stakes in the company. CWM LLC boosted its holdings in shares of MiMedx Group by 63.8% in the second quarter. CWM LLC now owns 4,857 shares of the company’s stock valued at $30,000 after buying an additional 1,892 shares during the period. PNC Financial Services Group Inc. raised its position in MiMedx Group by 1,808.4% during the second quarter. PNC Financial Services Group Inc. now owns 7,500 shares of the company’s stock worth $46,000 after acquiring an additional 7,107 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new stake in MiMedx Group in the 4th quarter valued at about $48,000. State of Alaska Department of Revenue bought a new position in MiMedx Group during the third quarter worth about $54,000. Finally, Headlands Technologies LLC acquired a new position in shares of MiMedx Group during the 2nd quarter worth approximately $72,000. 79.15% of the stock is owned by institutional investors.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.